Can Canopy Growth Stock Soar? The Consensus Seems Mixed

Investors considering Canopy Growth (TSX:WEED)(NYSE:CGC) stock have a lot to consider as we enter Q3.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Among the growth sectors investors have largely lost focus on of late is cannabis. Indeed, the amount of discussion around companies like Canopy Growth (TSX:WEED)(NYSE:CGC) stock has dwindled of late. With meme stocks soaring, and so many other opportunities for outlandish growth present in today’s market, this makes sense.

However, one could argue that cannabis stocks were the original meme stocks. These companies garnered a tremendous amount of attention in previous years. Indeed, as Canada legalized recreational cannabis use, the expectation was that a Biden government would follow.

However, we haven’t seen anything concrete play out yet south of the border. Accordingly, investor interest has seemingly shifted to other high-growth sectors today.

Let’s discuss what the outlook is for Canopy Growth stock and the other cannabis players in this sector.

Mixed consensus on Canopy Growth stock

Given the ambiguity with respect to U.S. legalization of cannabis at the federal level, analysts seem mixed in regards to the outlook for cannabis plays such as Canopy Growth stock.

Some analysts believe pending legalization could boost valuations in the sector. Indeed, this is a strong potential tailwind and should not be discounted by growth investors.

However, there are others who view Canopy Growth stock as too richly valued at these levels. Canaccord Genuity analyst Matt Bottomley is one such analyst. Accordingly, he has decreased his forward-looking revenue estimates for Canopy Growth.

Why?

Well, Canopy Growth fell well short of his estimates this past quarter. Declining international sales were the key culprit in this regard. Accordingly, Mr. Bottomley has revised his full-year forecast down on this recent underperformance.

John Zamparo, from CIBC, says that the latest top-line results of the company might hinder profitability. The analyst feels positive EBITDA is likely no earlier than Q2 2023. Despite this, Mr. Zamparo has kept a neutral rating while trimming his target from $30 to $27.

W. Andrew Carter from Stifel, however, maintains a sell rating for the company. He has reduced his target from $21 to $18.

Bottom line

Canopy Growth stock could outperform over the medium term, if everything works in its favour. The company’s plans to enter the U.S. market in a big way could provide a boost for investors speculating on another run in this high-growth sector.

However, recent results and the near- to medium-term outlook have turned some analysts sour on Canopy Growth stock. Accordingly, this is one I think will have a lot of volatility moving forward.

Unlike previous bull markets in cannabis, I don’t expect this one to be a linear move higher.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

More on Cannabis Stocks

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »